What is the recommended treatment approach for pediatric eosinophilic esophagitis?

Pediatric Eosinophilic Esophagitis: Treatment Approach

For pediatric eosinophilic esophagitis, initiate treatment with either proton pump inhibitors (PPIs) twice daily, topical corticosteroids, or empiric dietary elimination as first-line options, with the choice guided by patient/family preference, growth considerations, and disease severity. All three approaches are equally valid first-line therapies according to the most recent guidelines 1.

Treatment Algorithm

First-Line Treatment Options (Choose One)

1. Proton Pump Inhibitor Therapy

• Dosing: Twice daily for 8-12 weeks 1
• Efficacy: Achieves histological remission in approximately 45% of patients 1, 2
• Advantages: Excellent safety profile, ease of administration, preferred by many families
• Maintenance: Continue long-term if histological response achieved 1

2. Topical Corticosteroids

• Efficacy: Induces histological remission in 80-93% of patients 1, 3, 2
• Evidence Quality: HIGH grade evidence with STRONG recommendation 1
• Critical Point: Relapse rates are high after withdrawal—maintenance therapy is essential 1
• Formulations: Swallowed budesonide or fluticasone (designed for asthma but used off-label)
• Safety: Short-term studies show no increased adverse events versus placebo; long-term monitoring for adrenal suppression and growth in children is ongoing 3

3. Empiric Dietary Elimination

• Step-Up Approach (Recommended) 1:
  • Start: 2-food elimination (milk +/- wheat or egg) for 8-12 weeks
  • If no remission: Step up to 4-food elimination (milk, wheat, egg, soy) for 8-12 weeks
  • If no remission: Step up to 6-food elimination (add fish/shellfish, tree nuts/peanuts) for 8-12 weeks
• Efficacy: 43% remission with 2-food, 60% with 4-food, 79% with 6-food elimination 1
• Critical Requirement: Experienced dietitian support throughout elimination and reintroduction phases 1
• Pediatric Considerations: Monitor growth, nutritional adequacy, feeding behavior, and micronutrient deficiencies 1
• Important: Allergy testing (skin prick, IgE, patch testing) is NOT recommended for selecting foods to eliminate 1

Assessment of Response

Mandatory endoscopy with biopsies at 8-12 weeks while on treatment 1:

• Symptoms alone do NOT correlate reliably with histological activity
• Histological remission defined as <15 eosinophils per high-power field (0.3 mm²)
• Obtain at least 6 biopsies from multiple esophageal levels 1

Second-Line and Refractory Disease

If First-Line Therapy Fails:

• Dietary therapy: Step up to more restrictive elimination diet 1
• Consider combination therapy: Though not routinely recommended, can combine diet with pharmacological treatment in refractory cases 1
• Refer to allergist: For patients refractory to treatment or with significant concomitant atopic disease 1

Biologic Therapy (Dupilumab)

• Indication: Reserved for patients refractory to multiple prior treatments 4, 5
• Efficacy: Real-world data shows complete histological remission in treated pediatric patients 5
• Approval: FDA-approved for patients ≥1 year and ≥15 kg 4
• Evidence: Emerging but promising; limited pediatric data compared to adults 1, 4

Elemental Diet

• Efficacy: High (approaching 90%)
• Compliance: Very low
• Indication: Reserved ONLY for patients refractory to all other treatments 1

Maintenance Therapy

Long-term maintenance is essential 1:

• Continue the therapy that achieved remission indefinitely
• Topical steroids: Maintenance reduces risk of stricture development and food bolus obstruction 1
• PPIs: Effective for maintaining remission 1
• Diet: Continue identified trigger food avoidance

Monitoring Strategy

• Repeat endoscopy if symptoms recur while on treatment 1
• Early diagnosis and treatment may prevent long-term fibrostenotic complications 1
• Formal transition planning from pediatric to adult services improves outcomes 1

Common Pitfalls to Avoid

1. Do NOT rely on symptoms alone to assess treatment response—endoscopy with biopsies is mandatory 1
2. Do NOT use allergy testing to guide dietary elimination choices 1
3. Do NOT stop topical steroids after achieving remission without planning maintenance therapy—relapse is nearly universal 1
4. Do NOT skip multi-level biopsies—disease can be patchy, and normal-appearing mucosa may harbor eosinophils 5, 6
5. Do NOT use immunomodulators (azathioprine, 6-mercaptopurine) or anti-TNF/anti-integrin biologics—they are ineffective 1

Key Nuances

The 2022 BSG/BSPGHAN guidelines [1-1] represent the highest quality, most comprehensive evidence for pediatric EoE management. These guidelines emphasize that PPI-responsive esophageal eosinophilia is the same disease as non-PPI-responsive EoE 1, eliminating the outdated distinction. The choice between first-line therapies should be individualized based on family preference, growth concerns in young children, and practical considerations like medication adherence versus dietary restrictions.